140 related articles for article (PubMed ID: 12019849)
1. Comparative studies on the efficacy of MRI contrast agents in MRA.
Weinmann HJ; Bauer H; Ebert W; Frenzel T; Radüchel B; Platzek J; Schmitt-Willich H
Acad Radiol; 2002 May; 9 Suppl 1():S135-6. PubMed ID: 12019849
[No Abstract] [Full Text] [Related]
2. Contrast-enhanced magnetic resonance angiography in the coronary and peripheral arteries.
Saeed M; Wendland MF; Engelbrecht M; Sakuma H; Higgins CB
Acad Radiol; 1998 Apr; 5 Suppl 1():S108-12. PubMed ID: 9561057
[No Abstract] [Full Text] [Related]
3. Contrast-enhanced 3D-TOF MRA of peripheral vessels: intravascular versus extracellular MR contrast media.
Engelbrecht MR; Saeed M; Wendland MF; Canet E; Oksendal AN; Higgins CB
J Magn Reson Imaging; 1998; 8(3):616-21. PubMed ID: 9626876
[TBL] [Abstract][Full Text] [Related]
4. Gadolinium-enhanced off-resonance contrast angiography.
Edelman RR; Storey P; Dunkle E; Li W; Carrillo A; Vu A; Carroll TJ
Magn Reson Med; 2007 Mar; 57(3):475-84. PubMed ID: 17326177
[TBL] [Abstract][Full Text] [Related]
5. Use of intravascular contrast agents in MRI.
Bjørnerud A; Wendland MF; Johansson L; Ahlstrom HK; Higgins CB; Oksendal A
Acad Radiol; 1998 Apr; 5 Suppl 1():S223-5. PubMed ID: 9561086
[No Abstract] [Full Text] [Related]
6. Basic physics of MR contrast agents and maximization of image contrast.
Hendrick RE; Haacke EM
J Magn Reson Imaging; 1993; 3(1):137-48. PubMed ID: 8428081
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of liver-specific MRI contrast agents in rats with hepatitis and cirrhosis.
Kato N; Takahashi M; Ihara S; Tsujimoto T; Miyazawa T
Acad Radiol; 1998 Apr; 5 Suppl 1():S83-5. PubMed ID: 9561051
[No Abstract] [Full Text] [Related]
8. RES-specific imaging of the liver and spleen with iron oxide particles designed for blood pool MR-angiography.
Bremer C; Allkemper T; Baermig J; Reimer P
J Magn Reson Imaging; 1999 Sep; 10(3):461-7. PubMed ID: 10508309
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two blood pool contrast agents for 0.5-T MR angiography: experimental study in rabbits.
Clarke SE; Weinmann HJ; Dai E; Lucas AR; Rutt BK
Radiology; 2000 Mar; 214(3):787-94. PubMed ID: 10715047
[TBL] [Abstract][Full Text] [Related]
10. Comparison of iron oxide particles (AMI 227) with a gadolinium complex (Gd-DOTA) in dynamic susceptibility contrast MR imagings (FLASH and EPI) for both phantom and rat brain at 1.5 Tesla.
Loubeyre P; De Jaegere T; Bosmans H; Miao Y; Ni Y; Landuyt W; Marchal G
J Magn Reson Imaging; 1999 Mar; 9(3):447-53. PubMed ID: 10194716
[TBL] [Abstract][Full Text] [Related]
11. Ultrasmall superparamagnetic iron oxide-enhanced MR imaging of atherosclerotic plaque in hyperlipidemic rabbits.
Ruehm SG; Corot C; Vogt P; Cristina H; Debatin JF
Acad Radiol; 2002 May; 9 Suppl 1():S143-4. PubMed ID: 12019852
[No Abstract] [Full Text] [Related]
12. [New MR contrast media in liver diagnosis. Initial clinical results with hepatobiliary Eovist (gadolinium-EOB-DTPA) and RES-specific Resovist (SH U 555 A)].
Reimer P; Tombach B; Daldrup H; Hesse T; Sander G; Balzer T; Shamsi K; Berns T; Rummeny EJ; Peters PE
Radiologe; 1996 Feb; 36(2):124-33. PubMed ID: 8867429
[TBL] [Abstract][Full Text] [Related]
13. Combined SPIO-gadolinium magnetic resonance imaging in cirrhotic patients: negative predictive value and role in screening for hepatocellular carcinoma.
Guiu B; Loffroy R; Ben Salem D; Lepage C; Guiu S; Aho S; Jouve JL; Krausé D; Cercueil JP
Abdom Imaging; 2008; 33(5):520-8. PubMed ID: 17912584
[TBL] [Abstract][Full Text] [Related]
14. Optimization of a negative oral contrast agent for magnetic resonance imaging.
Davis MA; Mei H; Ritsema GH
Invest Radiol; 1994 Jun; 29 Suppl 2():S120-2. PubMed ID: 7928205
[No Abstract] [Full Text] [Related]
15. Contrast-enhanced MRI of focal liver lesions: differentiation and detection of primary and secondary liver lesions using Resovist-enhanced versus gadolinium-enhanced MRI in the same patient.
Hammerstingl R; Vogl TJ; Schwarz W; Kümmel S; Balzer T; Neuhaus P; Felix R
Acad Radiol; 1998 Apr; 5 Suppl 1():S75-9; discussion S93-4. PubMed ID: 9561049
[No Abstract] [Full Text] [Related]
16. New contrast agents for cardiovascular MRI and MRA.
Stillman AE
Int J Cardiovasc Imaging; 2001 Dec; 17(6):471-2. PubMed ID: 12365548
[No Abstract] [Full Text] [Related]
17. [Splenosis: value of MRI with injection of a superparamagnetic contrast agent].
Roussel A; Petit E; Mallet L; Zins M
J Radiol; 2008 Dec; 89(12):1944-6. PubMed ID: 19106854
[No Abstract] [Full Text] [Related]
18. Role of spatial distribution in proton relaxation enhancement by particulate iron oxide.
Tanimoto A; Yuasa Y; Stark DD
Invest Radiol; 1994 Jun; 29 Suppl 2():S78-80. PubMed ID: 7523329
[No Abstract] [Full Text] [Related]
19. MRI susceptometry: image-based measurement of absolute susceptibility of MR contrast agents and human blood.
Weisskoff RM; Kiihne S
Magn Reson Med; 1992 Apr; 24(2):375-83. PubMed ID: 1569876
[TBL] [Abstract][Full Text] [Related]
20. Contrast agents for magnetic resonance imaging: safety update.
Kirchin MA; Runge VM
Top Magn Reson Imaging; 2003 Oct; 14(5):426-35. PubMed ID: 14625469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
